Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase, rising over 16% in the afternoon trading session, attributed to strategic initiatives and upcoming financial announcements [1] Group 1: Stock Performance - As of the latest update, Huajian Medical's stock price is reported at 9.64 HKD, with a trading volume of 29.1585 million HKD [1] Group 2: Strategic Initiatives - The company announced a board meeting scheduled for August 29, 2025, to consider and approve the mid-term performance for the six months ending June 30, 2025, and to discuss potential interim dividends [1] - Since late July, Huajian Medical has launched several key strategic initiatives, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [1] - The company is pushing its U.S. subsidiary to apply for a stablecoin license and has partnered with BGI's subsidiary to establish the world's first "Innovative Drug Intellectual Property Tokenization Fund" [1] - On August 8, Huajian Medical officially launched the "Global Enhanced Ethereum (ETH) Treasury" strategy, collaborating with the licensed exchange HashKey and completing a compliant purchase of 149 million HKD in ETH [1] - Recently, the company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the medical innovation drug RWA trading platform [1]
港股异动 | 华检医疗(01931)午后涨超16% 公司今日将发布中期业绩 近期连续推出多项关键战略举措